Position in PTGX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$327,901
New position
Shares Held
2,675
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#240
of 338 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bayforest Capital Ltd holds $6,768,179 across 52 Biotechnology names. PTGX ranks #5 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RCUS |
Arcus Biosciences, Inc.
|
12,709 | $391,818 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
10,740 | $368,596 | |
| 3 | VRDN |
Viridian Therapeutics, Inc.\DE
|
19,775 | $363,266 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
2,674 | $354,920 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
This page
|
2,675 | $327,901 | |
| 6 | DNLI |
Denali Therapeutics Inc.
|
11,437 | $294,159 | |
| 7 | WVE |
Wave Life Sciences Ltd.
|
48,854 | $283,841 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
3,311 | $269,879 |
All Filings in PTGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $327,901 | 2,675 | Shares | Sole | 2026-08-05 | |
| No filing history on record for this holder in this stock. | ||||||